The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Malignant pheochromocytoma: current status and initiatives for future progress
Open accessAbstract
Pheochromocytomas are rare catecholamine-producing neuroendocrine tumors that are usually benign, but which may also present as or develop into a malignancy. Predicting such behavior is notoriously difficult and there are currently no curative treatments for malignant tumors. This report follows from a workshop at the Banbury Conference Center, Cold Spring Harbor, New York, on the 16th–18th November 2003, held to review the state of science and to facilitate future progress in the diagnosis and treatment of malignant pheochromocytoma. The rarity of the tumor and the resulting fragmented nature of studies, typically involving small numbers of patients, represent limiting factors to the development of effective treatments and diagnostic or prognostic markers for malignant disease. Such development is being facilitated by the availability of new genomics-based tools, but for such approaches to succeed ultimately requires comprehensive clinical studies involving large numbers of patients, stringently collected clinical data and tumor samples, and interdisciplinary collaborations among multiple specialist centers. Nevertheless, the well-characterized hereditary basis and the unique functional nature of these neuroendocrine tumors provide a useful framework that offers advantages for establishing the pathways of tumorigenesis and malignancy. Such findings may have relevance for understanding the basis of other more common malignancies where similar frameworks are not available. As the relevant pathways leading to pheochromocytoma are established it should be possible to take advantage of the new generation of drugs being developed to target specific pathways in other malignancies. Again the success of this will require well-designed and coordinated multicenter studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Greene, L. A., & Tischler, A. S. (1976) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.73.7.2424 · Cited by 5,553
Self-citationJOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
HOSKINS, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Self-citationBiochemical Diagnosis of Pheochromocytoma: Which Test Is Best?
Lenders, J. W. M., Pacak, K., Walther, M. M., Linehan, W. M., Mannelli, M., Friberg, P., Keiser, H. R., Goldstein, D. S., & Eisenhofer, G. (2002) · JAMA · doi:10.1001/jama.287.11.1427 · Cited by 1,134
Self-citationZerhouni, E. (2003) · Science · doi:10.1126/science.1091867 · Cited by 918
Thompson, L. D. R. (2002) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200205000-00002 · Cited by 715
Trends in Endocrinology and Metabolism 1998
Brines, R. (1998) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(98)00013-7 · Cited by 699
An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/−mice
Podsypanina, K., Lee, R. T., Politis, C., Hennessy, I., Crane, A., Puc, J., Neshat, M., Wang, H., Yang, L., Gibbons, J., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171060098 · Cited by 569
Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.
Gimenez‐Roqueplo, A., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Kien, P. K. V., Corvol, P. L., Plouin, P., & Jeunemaître, X. (2003) · PubMed · Cited by 547
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
Maloney, A., & Workman, P. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.1.3 · Cited by 531
The American journal of surgical pathology
Wilkins, L. W. (1977) · Cited by 501
Clinical Experience Over 48 Years With Pheochromocytoma
Goldstein, R. E., O’Neill, J. A., Holcomb, G. W., Morgan, W. M., Neblett, W. W., Oates, J. A., Brown, N., Nadeau, J., Smith, B., Page, D. L., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199906000-00001 · Cited by 464
Averbuch, S. D., Steakley, C. S., Young, R. C., Gelmann, E. P., Goldstein, D. S., Stull, R., & Keiser, H. R. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-109-4-267 · Cited by 427
Self-citationIlona Linnoila, R., Keiser, H. R., Steinberg, S. M., & Lack, E. E. (1990) · Human Pathology · doi:10.1016/0046-8177(90)90155-x · Cited by 374
VON RECKLINGHAUSEN′S DISEASE AND PHEOCHROMOCYTOMAS
Walther, M. M., Herring, J., Enquist, E., Keiser, H. R., & Linehan, W. M. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68171-2 · Cited by 361
The Tohoku Journal of Experimental Medicine
(1938) · Tubercle · doi:10.1016/s0041-3879(38)80099-4 · Cited by 328
Pheochromocytomas: Detection with18F DOPA Whole-Body PET—Initial Results
Hoegerle, S., Nitzsche, E., Altehoefer, C., Ghanem, N., Manz, T., Brink, I., Reincke, M., Moser, E., & Neumann, H. P. H. (2002) · Radiology · doi:10.1148/radiol.2222010622 · Cited by 325
Self-citationEuropean Journal of Surgical Oncology
Winters, Z., Balta, V., Afzal, M., Llewellyn-Bennett, R., Rayter, Z., Cook, J. C., Greenwood, R., & King, M. T. (2015) · Cited by 314
Loh, K.-C., Fitzgerald, P. A., Matthay, K. K., Yeo, P. P. B., & Price, D. C. (1997) · Journal of Endocrinological Investigation · doi:10.1007/bf03348026 · Cited by 278
Eisenhofer, G., Walther, M. M., Huynh, T.-T., Li, S.-T., Bornstein, S. R., Vortmeyer, A., Mannelli, M., Goldstein, D. S., Linehan, W. M., Lenders, J. W. M., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7496 · Cited by 267
Self-citationPheochromocytomas: can malignant potential be predicted?
John, H., Ziegler, W. H., Hauri, D., & Jaeger, P. (1999) · Urology · doi:10.1016/s0090-4295(98)00612-8 · Cited by 251
Pheochromocytoma: The expanding genetic differential diagnosis.
Bryant, J., Farmer, J., Kessler, L. J., Townsend, R. R., & Nathanson, K. L. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg024 · Cited by 250
Ilias, I., Yu, J., Carrasquillo, J. A., Chen, C. C., Eisenhofer, G., Whatley, M., McElroy, B., & Pacak, K. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030235 · Cited by 241
Self-citationClinical Development of 17-Allylamino, 17-Demethoxygeldanamycin
Sausville, E., Tomaszewski, J., & Ivy, P. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481831 · Cited by 225
Matthay, K. K., DeSantes, K., Hasegawa, B., Huberty, J., Hattner, R. S., Ablin, A., Reynolds, C. P., Seeger, R. C., Weinberg, V. K., & Price, D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.229 · Cited by 222
Eisenhofer, G., Huynh, T.-T., Pacak, K., Brouwers, F. M., Walther, M. M., Linehan, W. M., Munson, P. J., Mannelli, M., Goldstein, D. S., & Elkahloun, A. G. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00838 · Cited by 207
Self-citationPhaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland
McNeil, A. R., Blok, B. H., Koelmeyer, T. D., Burke, M. P., & Hilton, J. M. (2000) · Australian and New Zealand Journal of Medicine · doi:10.1111/j.1445-5994.2000.tb04358.x · Cited by 195
High‐dose 131I‐metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma
Rose, B., Matthay, K. K., Price, D., Huberty, J., Klencke, B., Norton, J. A., & Fitzgerald, P. A. (2003) · Cancer · doi:10.1002/cncr.11518 · Cited by 158
Angiogenesis and Vascular Architecture in Pheochromocytomas
Favier, J., Plouin, P., Corvol, P. L., & Gasc, J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64400-8 · Cited by 156
Schlumberger, M. J., Gicquel, C., Lumbroso, J., Tenenbaum, F., Comoy, E., Bosq, J., Fonseca, E., Ghillani‐Dalbin, P., Aubert, B., Travagli, J. P., et al. (1992) · Journal of Endocrinological Investigation · doi:10.1007/bf03345807 · Cited by 156
Clinical and Experimental Pheochromocytoma
Messerli, F. H. (1997) · JAMA · doi:10.1001/jama.1997.03550010092050 · Cited by 155
Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice
You, M. J., Castrillón, D. H., Bastian, B. C., O’Hagan, R. C., Bosenberg, M., Parsons, R. E., Chin, L., & DePinho, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022632099 · Cited by 153
Australian and New Zealand Journal of Medicine
(2010) · Australian and New Zealand Journal of Medicine · doi:10.1111/(issn)1445-5994a · Cited by 146
Smith‐Hicks, C. L., Sizer, K. C., Powers, J. F., Tischler, A. S., & Costantini, F. D. (2000) · The EMBO Journal · doi:10.1093/emboj/19.4.612 · Cited by 145
Self-citationTenenbaum, F., Lumbroso, J., Schlumberger, M. J., Mure, A., Plouin, P., Caillou, B., & Parmentier, C. (1995) · PubMed · Cited by 139
Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice
Powers, J. F., EVINGER, M. J. Q., Tsokas, P., Bedri, S., Alroy, J., Shahsavari, M., & Tischler, A. S. (2000) · Cell and Tissue Research · doi:10.1007/s004410000290 · Cited by 130
Self-citationElder, E. E., Xu, D., Höög, A., Enberg, U., Hou, M., Pisa, P., Gruber, A., Larsson, C., & Bäckdahl, M. (2003) · Modern Pathology · doi:10.1097/01.mp.0000056982.07160.e3 · Cited by 126
Dannenberg, H., Speel, E. M., Zhao, J., Saremaslani, P., van der Harst, E., Roth, J., Heitz, P. U., Bonjer, H. J., Dinjens, W. N. M., Mooi, W. J., et al. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64547-6 · Cited by 110
Vascular Endothelial Growth Factor Receptor-3
Taipale, J., Mäkinen, T., Arighi, E., Kukk, E., Karkkainen, M. J., & Alitalo, K. K. (1999) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-59953-8_5 · Cited by 107
The value of plasma markers for the clinical behaviour of phaeochromocytomas
van der Harst, E., de Herder, W., de Krijger, R. R., Bruining, H. A., Bonjer, H. J., Lamberts, S., van den Meiracker, A. H., Stijnen, T., & Boomsma, F. (2002) · European Journal of Endocrinology · doi:10.1530/eje.0.1470085 · Cited by 107
Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?
van der Harst, E., Bruining, H. A., Bonjer, H. J., van der Ham, F., Dinjens, W. N. M., Lamberts, S. W. J., de Herder, W. W., Koper, J. W., Stijnen, T., Proye, C. A. G., et al. (2000) · The Journal of Pathology · Cited by 103
Malignant Pheochromocytoma: Chromaffin Granule Transmitters and Response to Treatment
Rao, F., Keiser, H. R., & O’Connor, D. T. (2000) · Hypertension · doi:10.1161/01.hyp.36.6.1045 · Cited by 96
Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues
Wiseman, G. A., & Kvols, L. K. (1995) · Seminars in Nuclear Medicine · doi:10.1016/s0001-2998(95)80016-6 · Cited by 94
Use ofm-[131I]Iodobenzylguanidine in the Treatment of Malignant Pheochromocytoma
Krempf, M., Lumbroso, J., Mornex, R., Brendel, A., Wémeau, J.-L., Delisle, M. J., Aubert, B., CARPENTIER, P., Fleury-Goyon, M. C., Gibold, C., et al. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-72-2-455 · Cited by 91
Treatment of Malignant Pheochromocytomas With 131-I Metaiodobenzylguanidine and Chemotherapy
Sisson, J. C., Shapiro, B., Shulkin, B. L., Urba, S. G., Zempel, S., & Spaulding, S. (1999) · American Journal of Clinical Oncology · doi:10.1097/00000421-199908000-00008 · Cited by 87
Self-citationRadiofrequency Ablation: a Novel Approach for Treatment of Metastatic Pheochromocytoma
Pacák, K., Fojo, T., Goldstein, D. S., Eisenhofer, G., Walther, M. M., Linehan, W. M., Bachenheimer, L. C., Abraham, J., & Wood, B. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.8.648 · Cited by 85
Self-citationBrauch, H. B., Hoeppner, W., Jähnig, H., Wöhl, T., Engelhardt, D., Spelsberg, F. W., & Ritter, M. M. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4454 · Cited by 84
Miskulin, J., Shulkin, B. L., Doherty, G. M., Sisson, J. C., Burney, R. E., & Gauger, P. G. (2003) · Surgery · doi:10.1016/s0039-6060(03)00416-1 · Cited by 83
Self-citationBoltze, C., Mundschenk, J., Unger, N., Schneider‐Stock, R., Peters, B., Mawrin, C., Hoang‐Vu, C., Roessner, A., & Lehnert, H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021299 · Cited by 82
Self-citationHofstra, R. M. W., Stelwagen, T., Stulp, R. P., Jong, D. D., Hulsbeek, M. M. F., Kamsteeg, E.-J., van den Berg, A., Landsvater, R. M., Vermey, A., Molenaar, W. M., et al. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.8.8768845 · Cited by 79
Radioisotope diagnosis and therapy of malignant pheochromocytoma
Shapiro, B., Gross, M. D., & Shulkin, B. L. (2001) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(01)00492-1 · Cited by 74
Self-citationIncreased Expression of Cyclooxygenase-2 in Malignant Pheochromocytomas
Salmenkivi, K., Haglund, C. H., Ristimaki, A. P., Arola, J. T., & Heikkilä, P. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8052 · Cited by 73
Shapiro, B., Sisson, J. C., Wieland, D. M., Mangner, T. J., Zempel, S., Mudgett, E. E., Gross, M. D., Carey, J. E., Zasadny, K. R., & Beierwaltes, W. H. (1991) · PubMed · Cited by 71
Kopf, D., Bockisch, A., Steinert, H. C., Hahn, K. M., Beyer, J., Neumann, H. P. H., Hensen, J., & Lehnert, H. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1738.x · Cited by 69
Self-citationBenn, D. E., Dwight, T., Richardson, A. L., Delbridge, L., Bambach, C. P., Stowasser, M., Gordon, R. D., Marsh, D. J., & Robinson, B. G. (2000) · PubMed · Cited by 69
VEGF in 105 pheochromocytomas: enhanced expression correlates with malignant outcome
Salmenkivi, K., HEIKKIL, P., Liu, J., Haglund, C. H., & Arola, J. T. (2003) · Apmis · doi:10.1034/j.1600-0463.2003.1110402.x · Cited by 65
Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes
Bauters, C., Vantyghem, M., Leteurtre, E., Odou, M., Mouton, C., Porchet, N., Wemeau, J.-L., Proye, C., & Pigny, P. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.6.e75 · Cited by 65
Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-Up.
Kebebew, E., & Duh, Q. (1998) · PubMed · Cited by 59
Zielke, A., Middeke, M., Hoffmann, S., Colombo‐Benkmann, M., Barth, P. J., Hassan, I., Wunderlich, A. C., Hofbauer, L. C., & Duh, Q. (2002) · Surgery · doi:10.1067/msy.2002.128613 · Cited by 58
Yon, L., Guillemot, J., Montero‐Hadjadje, M., Grumolato, L., Leprince, J., Lefèbvre, H., Contesse, V., Plouin, P., Vaudry, H., & Anouar, Y. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021748 · Cited by 56
Tanaka, S., Ito, T., Tomoda, J., Higashi, T., Yamada, G., & Tsuji, T. (1993) · Internal Medicine · doi:10.2169/internalmedicine.32.789 · Cited by 56
Lamarre-Cliché, M., Gimenez‐Roqueplo, A., Billaud, E. M., Baudin, É., LUTON, J. P., & Plouin, P. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01658.x · Cited by 54
Clinical and Experimental Pheochromocytoma
Cryer, P. E. (1997) · The Endocrinologist · doi:10.1097/00019616-199707050-00013 · Cited by 53
Brauch, H. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4101 · Cited by 51
Lehnert, H., Mundschenk, J., & Hahn, K. (2003) · KARGER eBooks · doi:10.1159/000074663 · Cited by 45
Self-citationKhorram‐Manesh, A., Ahlman, H., Jansson, S. K. G., & Nilsson, O. (2002) · Endocrine Pathology · doi:10.1385/ep:13:2:099 · Cited by 41
Takahashi, K., Ashizawa, N., Minami, T., Suzuki, S., Sakamoto, I., Hayashi, K., Tomiyasu, S., Sumikawa, K., Kitamura, K., Eto, T., et al. (1999) · Internal Medicine · doi:10.2169/internalmedicine.38.349 · Cited by 39
Aguiar, R. C. T. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2890 · Cited by 38
Gross, D. J., Reibstein, I., Weiss, L., Slavin, S., Dafni, H., Neeman, M., Pines, M., & Nagler, A. (2003) · PubMed · Cited by 37
Increased Expression of Tenascin in Pheochromocytomas Correlates With Malignancy
Salmenkivi, K., Haglund, C., Arola, J. T., & Heikkilä, P. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200111000-00010 · Cited by 36
Boyd, M., Mairs, R. J., Mairs, S. C., Wilson, L., Livingstone, A., Cunningham, S. H., Brown, M. M., Nicol, M. Q., & Keith, W. N. (2001) · Oncogene · doi:10.1038/sj.onc.1204955 · Cited by 34
Effect of Octreotide on Catecholamine Plasma Levels in Patients with Chromaff in Cell Tumors
Invitti, C., Martin, M. D., Bolla, G. B., Giraldi, F. P., Maestri, E., Leonetti, G., & Cavagnini, F. (1993) · Hormone Research · doi:10.1159/000183786 · Cited by 31
Neumann, D. R., Basile, K. E., Bravo, E. L., et al. (1996) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199603000-00028 · Cited by 27
Gene Expression Profiling of Endocrine Tumors Using DNA Microarrays: Progress and Promise
Giordano, T. J. (2003) · Endocrine Pathology · doi:10.1385/ep:14:2:107 · Cited by 17
Self-citation[131I]metaiodobenzylguanidine treatment of malignant pheochromocytoma: experience of the Rome group.
Troncone, L., Rufini, V., Ms, D., De Santis, M., & Luzi, S. (1991) · PubMed · Cited by 17
Kimura, N., Sasano, N., Miura, Y., & KOBAYASHI, K. (1984) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.142.1 · Cited by 14
Cited by
Lenders, J. W., Eisenhofer, G., Mannelli, M., & Pacak, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,524
Self-citationGenetic Testing in Pheochromocytoma or Functional Paraganglioma
Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O., Chamontin, B., Delemer, B., Giraud, S., Murat, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1484 · Cited by 684
Pheochromocytoma: recommendations for clinical practice from the First International Symposium
Pacak, K., Eisenhofer, G., Ahlman, H., Bornstein, S. R., Gimenez-Roqueplo, A.-P., Grossman, A. B., Kimura, N., Mannelli, M., McNicol, A. M., & Tischler, A. S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0396 · Cited by 680
Self-citationAmar, L., Baudin, E., Burnichon, N., Peyrard, S., Silvera, S., Bertherat, J., Bertagna, X., Schlumberger, M., Jeunemaitre, X., Gimenez-Roqueplo, A.-P., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0709 · Cited by 450
Ayala-Ramirez, M., Feng, L., Johnson, M. M., Ejaz, S., Habra, M. A., Rich, T., Busaidy, N., Cote, G. J., Perrier, N., Phan, A., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1946 · Cited by 428
Metadata
- Authors
- Eisenhofer, G., Bornstein, S. R., Brouwers, F. M., Cheung, N.-K. V., Dahia, P. L., de Krijger, R. R., Giordano, T. J., Greene, L. A., Goldstein, D. S., Lehnert, H., Manger, W. M., Maris, J. M., Neumann, H. P. H., Pacak, K., Shulkin, B. L., Smith, D. I., Tischler, A. S., & Young, W. F.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2004-09
- Volume
- 11
- Issue
- 3
- Pages
- 423-436
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2131438124
- Cited by
- 338
- References
- 76
- FWCI
- 19.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.